Cardiovascular

Five things for pharma marketers to know: Tuesday, June 30

Five things for pharma marketers to know: Tuesday, June 30

By

Vertex's cystic-fibrosis drug approval likely to come this week; Roche's multiple-sclerosis treatment hits primary and secondary endpoints; Regeneron/Sanofi debut film about high cholesterol

Five things for pharma marketers to know: Tuesday, June 23

Five things for pharma marketers to know: Tuesday, June 23

By

Adults dominate the ADHD prescription category; the FDA approved The Medicine Company's anticlotting drug 10 years after issuing a CRL; a survey shows personalized content can build consumer goodwill

Studies show blood thinner antidotes work

Clinical trial results for experimental antidotes to oral anticoagulants Pradaxa and Eliquis indicate they reverse blood thinners in a short time.

Survey shows doctors ready for PCSK9s

Survey shows doctors ready for PCSK9s

By

Cardiologists are more likely to prescribe the experimental drugs than are primary-care physicians.

Some heartburn drugs linked to increased risk of heart attack

A data-mining analysis of patient records found a significant increase in the chance of heart attack for those taking proton-pump inhibitors.

Five things for pharma marketers to know: Thursday, June 11

Five things for pharma marketers to know: Thursday, June 11

By

Amgen's PCSK9 inhibitor is the second in its class to get an FDA panel endorsement; a new drug could threaten Shire's hold on a rare-disease category; a study shows pharma invests less in Hispanic audiences than in other groups

Five things for pharma marketers to know: Wednesday, June 10

Five things for pharma marketers to know: Wednesday, June 10

By

FDA panel recommends Sanofi/Regeneron's PCSK9 inhibitor for approval; Merck and Samsung collaboration says their rheumatoid arthritis biosimilars are equivalent to the biologic versions; Bayer offloads its diabetes-care business

Five things for pharma marketers to know: Tuesday, June 9

Five things for pharma marketers to know: Tuesday, June 9

By

Study shows Merck's Januvia does not increase heart risks; a former Genentech exec launches a behavioral health business; lawmakers want black-box warnings on more opioids

PCSK9 adcomm preview: what's at stake

PCSK9 adcomm preview: what's at stake

By

An FDA advisory committee will sound off on the future of cholesterol-lowering treatments this week, discussing if Sanofi/Regeneron's Praluent and Amgen's Repatha warrant marketing approval.

Five things for pharma marketers to know: Friday, June 5

Five things for pharma marketers to know: Friday, June 5

By

FDA panel recommends approval of female Viagra; FDA says that Sanofi's and Regeneron's PCSK9 inhibitor lowers LDL; GSK cuts 350 jobs

Five things for pharma marketers to know: Tuesday, May 26

Five things for pharma marketers to know: Tuesday, May 26

By

Experimental psoriasis drug linked to suicidal thoughts; analysis finds that some high prescribers receive non-research industry money; researchers say new MS drugs spur higher prices of older medications

Five things for pharma marketers to know: Tuesday, May 5

Five things for pharma marketers to know: Tuesday, May 5

By

Worldwide spending on cancer medications hit $100 billion last year; Bayer adds an anticoagulant to its pipeline for $100 million; GlaxoSmithKline has a new chairman

Five things for pharma marketers to know: Friday, May 1

Five things for pharma marketers to know: Friday, May 1

By

Nexium tops the list of Medicare's spending on brand drugs; Gilead Sciences doubles its first-quarter profit; Pfizer reportedly wants to buy a rare-disease drug company

Bristol-Myers Squibb sales rise, led by Eliquis and Opdivo

Bristol-Myers Squibb sales rise, led by Eliquis and Opdivo

By

Newly approved Opdivo added $40 million to the quarter's product sales, which rose 8.9% compared to the year-earlier period.

PCSK9 antibodies are safe and effective, analysis concludes

PCSK9 antibodies reduced overall mortality and lowered LDL cholesterol levels in more than 10,000 patients in Phase-II/III clinical trials.

Sales rise as Amgen outlines cardiovascular strategy

Sales rise as Amgen outlines cardiovascular strategy

By

Established products fueled at 12% jump in first-quarter sales.

FDA committee recommends label change for Onglyza

FDA committee recommends label change for Onglyza

By

Despite an FDA committee voting that AstraZeneca's diabetes medication carries an acceptable heart risk, analysts say a Merck study will determine the DPP-IV category's fate.

Five things for pharma marketers to know: Wednesday, April 15

Five things for pharma marketers to know: Wednesday, April 15

By

An FDA panel said heart risks should be part of Onglyza's label; the OIG will examine generic price increases; Abbott said its OTC glucose meter will save patients money

Pfizer offers grants for PCSK9 research

The drugmaker is calling on researchers to investigate PCSK9s in specific areas of interest.

Five things for pharma marketers to know: Tuesday, April 7

Five things for pharma marketers to know: Tuesday, April 7

By

Merck funds protein-degrading technology; Shire expects approval for a new ADHD medication in 2017; state biosimilar notification laws focus on subtext

Bayer expands MIT/Harvard collaboration

The focus will now include cardiovascular disease.

Physicians call for emphasis on women's health research and care

Physicians call for emphasis on women's health research and care

By

Panelists at a healthcare innovation conference said clinical research and local physician practices need to do more for women's health.

Five things for pharma marketers to know: Tuesday, March 17

Five things for pharma marketers to know: Tuesday, March 17

By

Interim results show cancer drug Imbruvica works well with other treatments; two studies show pricey new HCV medications are cost effective; the American College of Physicians wants less cardiac testing

PCSK9 drugs show viability, tolerability

PCSK9 drugs show viability, tolerability

By

Amgen and Sanofi/Regeneron shared clinical trial data that shows PCSK9 inhibitors dropped LDL levels by around 60%.

FDA approves Boston Scientific atrial fibrillation device

The approval follows three advisory panel reviews and a complete response letter.

Pradaxa antidote goes to FDA

The breakthrough designation therapy drug was the first for its drug class.

BI rare-disease awareness push slated for Saturday

Industry rare disease awareness efforts included a pipeline overview at Pfizer as well as BI's efforts to draw attention to IPF.

Poll highlights cholesterol knowledge gap

Poll highlights cholesterol knowledge gap

By

Americans may be taking anti-cholesterol medications, but it doesn't mean they are aware of their impact.

Five things for pharma marketers to know: Thursday, February 19

Five things for pharma marketers to know: Thursday, February 19

By By

Lilly delays Phase-III cholesterol drug results; PatientsLikeMe and Walgreens team up for "drug reaction reviews"; Roche skin-cancer drug receives Priority Review.

Specialty medications have PBMs on edge

Specialty medications have PBMs on edge

By

CVS health execs write that cost of long-term specialty medications, not short-timers like Sovaldi, are a major worry.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.